Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma

NCT06600321 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.

NCT NCT06600321
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06600321 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of ALN-BCAT as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Lead sponsor
Alnylam Pharmaceuticals
Phase
Phase 1
Overall status
Recruiting
Start date
December 30, 2024
Completion date
October 31, 2027
Enrollment
158 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hepatocellular carcinoma, metastatic hepatocellular carcinoma